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Prevalence and risk factors associated with
sexually transmitted infections (STIs)
among women of reproductive age in
Swaziland
Themba G. Ginindza1*, Cristina D. Stefan2, Joyce M. Tsoka-Gwegweni1, Xolisile Dlamini3, Pauline E. Jolly4,
Elisabete Weiderpass5,6,7,8, Nathalie Broutet9 and Benn Sartorius1
Abstract
Background: Sexually transmitted infections (STIs) remain an important public health problem with approximately
half a billion new cases annually among persons aged 15–49 years. Epidemiological data on STIs among women of
reproductive age in Swaziland are limited. The availability of epidemiological data on STIs and associated risk factors
in this population is essential for the development of successful prevention, diagnosis and management strategies
in the country. The study aimed to determine the prevalence and risk factors associated with STIs.
Methods: A total of 655 women aged 15–49 years were systematically enrolled from five health facilities using a
cross-sectional study design. Cervical specimen were tested using GeneXpert CT/NG Assays for Chlamydia
trachomatis (CT) and Neisseria gonorrhoeae (NG), GeneXpertTV Assay for Trichomonas vaginalis (TV), and GeneXpert
HPV Assays for hr-HPV. Blood samples were tested using Alere Determine HIV-1/2Ag/Ab Combo and Trinity Biotech
Uni-Gold Recombigen HIV test for confirmation for HIV, and Rapid Plasma Reagin and TPHA test for confirmation
for Treponema pallidum (syphilis). Genital warts were assessed prior to specimen collection. Survey weighted
analyses were done to estimate the population burden of STIs.
Results: The four most common curable STIs: CT, NG, TV, Treponema pallidum (syphilis), as well as genital warts were
considered in this study. The overall weighted prevalence of any of these five STIs was 19.4% (95% CI: 14.9–24.8),
corresponding to 72 990 women with STIs in Swaziland. The estimated prevalences were 7.0% (95% CI: 4.1–11.2) for CT, 6.
0% (95% CI: 3.8–8.8) for NG, 8.4% (95% CI: 5.4–12.8) for TV, 1.4% (95% CI: 1.1–10.2) for syphilis and 2.0% (95% CI: 1.0–11.4)
for genital warts. The overall weighted HIV prevalence was 42.7% (95%CI: 35.7–46.2). Among hr-HPV positive women, 18.
8% (95% CI: 13.1–26.3) had one STI, while 6.3% (95% CI: 3.3–11.7) had multiple STIs. Risk factors associated with STIs were
being employed (OR = 2.2, 95% CI: 1.0–4.7), self-employed (OR = 2.8, 95% CI: 1.5–5.5) and being hr-HPV positive (OR = 2.0,
95% CI: 1.3–3.1). Age (0.9, 95% CI: 0.8–0.9), being married (OR = 0.4, 95% CI: 0.3–0.7) and not using condoms with regular
partners (OR = 0.5, 95% CI: 0.3–0.9) were inversely associated with STIs.
Conclusion: STIs are highly prevalent among women of reproductive age in Swaziland. Thus, a comprehensive STIs
screening, surveillance and treatment programme would be justified and could potentially lower the burden of STIs in
the country.
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Background
Globally, sexually transmitted infections (STIs) remain a
significant public health problem mainly in low-income
countries [1, 2]. Currently, approximately half a billion
new cases occur worldwide each year [3], and more than
one million STIs are acquired per day [4]. Of the
estimated total of 357 million incident cases of the cur-
able STIs world-wide, 131 million are from Chlamydia
trachomatis (CT), 78 million are from Neisseria gonor-
rhea (NG), 5.6 million are from syphilis and 143 million
are from Trichomonas vaginalis (TV) cases [3, 4]. The
World Health Organization (WHO) further estimated
that 8.3, 21.1 and 59.7 million new cases of CT, NG and
TV infections respectively, occur in sub-Saharan Africa
(SSA), with the majority of new STIs occurring among
the population aged 15 to 49 years [5].
Depending on which STI and the population, in low-
income countries largely in SSA, NG, CT, TV, Human
papillomavirus (HPV), herpes, and syphilis increase the
risk of HIV acquisition and transmission between two to
eight fold [4, 6–9]. Furthermore, the inflammation
resulting from viral and non-viral STIs increases viral
shedding of HIV-1 in the genital tract [10–12] and also
increases the risk of HIV-1 transmission to the sex part-
ners [13, 14]. It is estimated that the probability of HIV
transmission per sexual contact is 6% if either partner
has another STI other than HIV [15] as compared to
0.2% in the absence of STIs [16]. The impact of co-
infection of HPV with HIV in the SSA has increased the
burden of cervical diseases (such as cervical lesions and
cancer), since HIV infected women have a higher preva-
lence of hr-HPV [17]. Furthermore, STIs such as NG
and CT are the major causes of pelvic inflammatory
disease (PID) and infertility in women [4]. In low-
income countries, impairments associated with STIs are
a major cause of mother and child mortality and mor-
bidity in adolescence and also during pregnancy [18, 19].
Factors affecting the spread of STIs, including HIV,
have been documented in many epidemiological studies
across different populations [20–24]. STIs and HIV share
the same behavioral, socioeconomic and demographic
risk factors [20, 25], including age at first sexual inter-
course, inconsistent condom use, having multiple sexual
partners, female sex, being single and the partner’s
sexual behaviour, location and culture. Furthermore,
HIV infection increases the of other STIs [20, 24–28].
There is limited information on the prevalence and risk
factors associated with STIs at population level in
Swaziland, the country which has the highest prevalence of
HIV infection worldwide. The availability of
epidemiological data on STIs and associated risk factors in
this population is essential for the development of success-
ful prevention, diagnosis and management strategies in the
country [29]. This study was therefore, conducted to
determine the prevalence and risk factors associated with
STIs among women of reproductive age in Swaziland.
Methods
Study setting and population
The study participants were women aged 15–49 years at-
tending five healthcare facilities for routine healthcare and
related services such as family planning, vaccination etc.,
from June to July 2015. This cross-sectional study in-
cluded all women of reproductive age with a history of or
who are currently sexually active and who provided writ-
ten informed consent. The health care facilities (Mbabane
Government hospital, Realign Fitkin Memorial (RFM)
hospital, Hlatsikhulu hospital, Sithobela hospital and Siteki
Public Health Unit) were located within the four political
regions of Swaziland as shown in Table 1. The selection of
the sites was based on the criteria of having fully function-
ing cervical cancer screening services, such as visual in-
spection with acetic acid (VIA) and cryotherapy. The
purpose of including all fully functioning cervical cancer
screening units was to achieve the goal of the ‘see and
treat” approach. All health facilities were using the “see
and treat” approach as at the time of the study. VIA was
performed, and all those who were VIA-positive were
treated with cryotherapy and followed for 12 months.
However, these results are not reported in this article.
Sample size
The sample size determination was based on the main
research project aim, namely of establishing the burden
of HPV infection and HPV-related conditions among
women of reproductive age in Swaziland, where the
value of the parameter(s) were not known in Swaziland.
The prevalence of STIs investigated in the study was a
secondary objective. Hence, the use of 50%, which
assumes maximum variability and the largest possible
sample size, given the predefined precision of ±5% and
95% confidence (5% type I error). Based on this a, sam-
ple size of 384 subjects was required to be used. The
sample was further increased by a margin of 10% to
Table 1 Study sites per region and number of participants per
site
Regions Study site Code Sites Participants
per-site
Hhohho H01 Mbabane government
hospital
182
Manzini H02 RFM hospital 196
Lubombo H03 Siteki Public Health Unit
(PHU)
69
H04 Sithobela Hospital 69
Shiselweni H05 Hlathikhulu Hospital 139
Total 5 655
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account for potential non-response and multiplied by a
design effect (D) of 1.5. The final calculated sample size
of the study was 650 women. However, a total of 655
women participated to the study.
Sampling strategy
The recruitment of participants was done in two
sampling stages. Firstly, women were stratified by age
(seven age-groups) and then sampled in each site using
systematic random sampling (every third woman of each
age), using the lottery method. The participants were
selected from each site until the calculated sample size
was achieved per site.
Data collection
Prior to questionnaire administration, willing partici-
pants were given all the necessary information about the
study, their potential contribution, and their risks and
benefits before they signed the informed consent form.
Furthermore, all necessary information was included in
the study information sheet and informed consent docu-
ments. A structured standardized questionnaire was
administered by trained nurses to obtain detailed data
on socio-demographic characteristics, and sexual, repro-
ductive and gynaecologic histories. Thereafter, the nurse
midwife inspected the perineal, vulvar, vaginal and
cervical regions of each woman for evidence of genital
warts, ulcers, discharge, inflammation or tenderness, and
recorded all abnormalities according to the study proto-
col. Lastly, the specimen collection for each of the tests
was performed (see details below). All participants found
to be exhibiting genital warts were treated with the
WHO-recommended 0.5% podophyllin tincture. Add-
itionally, all participants presenting with STIs on
syndromic diagnosis or/and who tested positive for STIs,
were treatment as per WHO STIs management guide-
lines [4], which have been adopted by the Ministry of
Health. Thereafter, the participants were invited to re-
turn in 1 week for review purposes as recommended by
the guidelines. Participants were also requested to
communicate with their sexual partners their need to
visit the clinic or seek treatment, using the provided tra-
cing slip with a suspected STI code of treatment.
Data were entered using EpiData 3.02 for Windows
(The Epi Data Association Odense, Denmark). Each
participant was assigned a unique study identity number
that was used to link the questionnaire and the bio-
logical specimens. Personal information was blinded
from the researcher and was kept on site for feedback of
the results to the women, and validation of data.
Biological specimen collection and testing
After visual inspection of the vulva, a non-lubricated
sterile disposable speculum was inserted and cervical
cells were collected using the Xpert CT/NG/TV Endo-
cervical swab (CT/NG/TV SWAB-50) (Cepheid, Sunny-
vale, CA, 2014). After HIV pre-counselling, two 4 mL
samples of blood (for HIV and syphilis testing) were col-
lected in a vacutainer tube from participants consenting
to HIV testing. All specimens were collected and trans-
ported daily to the National Referral Laboratory (NRL).
Specimen testing
All specimens testing were tested at the NRL, Mbabane,
Swaziland. Since this work is part of the HPV/Cervical
cancer study, only overall weighted HPV and HIV preva-
lence results are presented in this paper, for a purpose of
assessing the association between the curable STIs and
HPV and HIV.
CT/NG and TV testing
Cepheid Xpert CT/NG assay was used to detect Chla-
mydia trachomatis (CT) and Neisseria gonorrhea (NG)
infection, and the Cepheid Xpert TV Assay was used to
detect Trichomonas vaginalis (TV) (Cepheid, Sunnyvale,
CA, 2014) [30, 31]. All tests were performed according
to the manufacturers’ instructions. These are real-time
polymerase chain reaction (PCR)-based assays for the
simultaneous detection of CT/NG and TV from endo-
cervical specimens.
Treponema pallidum (syphilis)
Treponema pallidum (Syphilis) testing was routinely
conducted on all participants who consented to HIV test-
ing using a commercially available standard Rapid Plasma
Reagin (RPR) test (Atlas Medical, Cambridge, UK) [32],
following the manufacturer’s instructions. All reactive
specimens were confirmed by Treponema pallidum
Hemagglutination Assay (TPHA) (Omega Diagnostic,
Scotland, UK) [33].
HPV testing
The HPV-DNA testing was done using the GeneXpert
HPV assay (Xpert HPV Assay) (Cepheid, Sunnyvale, CA,
2014) [34] according to the manufacture’s protocol. The
Xpert HPV test gives results from six separate channels:
(i) sample adequacy control (SAC), (ii) P1-HPV16, (iii)
P2-HPV18/45, (iv) P3-HPV 31/33/35/52/58, (v) P4-
HPV51/59 and (vi) P5-HPV39/68/56/66. An individual
specimen can be positive for more than one probe.
HIV testing
The Alere Determine HIV-1/2 Ag/Ab Combo test was
used to detect both HIV-1/2 antibodies and free HIV-1
p24 antigen [35]. Reactive specimens were confirmed by
Trinity Biotech Uni-Gold Recombigen HIV Test [36].
All participants who tested HIV positive were post-
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counselled and referred to health units offering the ne-
cessary HIV treatment, care and support services.
Data and statistical analysis
Data were processed and analysed using Stata 13.0SE
(Stata corp. College station, Texas, USA). Data were
checked for possible errors and missing values prior to
analysis. Age and region-weighted analyses were done to
estimate the overall STIs’ prevalence and coinfection
with HIV and hr-HPV.
Survey weighted analysis was done to adjust the sam-
ple characteristic to match the target population (15–49)
that they were selected to represent. It is applied to
bring the proportion of women in the sample in align-
ment with the portion of women in the target popula-
tion. Therefore, all results are reported as weighted.
Survey weighted prevalence and 95% confidence inter-
vals (CI) were calculated. In addition, assuming that our
study subjects were representative of the female popula-
tion of the same age strata, we used survey weights to
extrapolate sample proportions to population totals
(age-region weighted) to estimate burden counts, based
on the 2007–2030 population projections aligned to the
estimated 2014 population of 377 169 women aged 15–
49 years [37]. Differences in prevalence by categorical
variables such as site, age, HIV and hr-HPV were
assessed using the survey weighted chi-square (χ2) test.
Odds ratios (unadjusted and adjusted) and 95% CIs for
potential risk factors associated with STIs were esti-
mated using survey weighted logistic regression models.
Variables that were significant at a cut-off of 0.2 in the
bivariate regression analyses were selected for inclusion
into the final multivariable model. An adjusted p-value
of <0.05 was deemed statistically significant.
Results
Characteristics of the study population
A total of 655 women were enrolled in the study within
the period of June - July 2015. All the participants had
sufficient specimens for the four non-viral STIs testing
and only 11 had sufficient specimen for hr-HPV. Table 2
summarizes the key characteristics of the study popula-
tion. The mean ages (± standard deviation [SD]) for
enrolled women was 32.2 (±8.7) years. Their mean age
at menarche was 14.4 (±1.7) years, at first intercourse
was 17.9 (±2.9) years, and at first pregnancy was 19.4
(±3.9) years. Of the 655 participants, 571 (88.7%) had
been pregnant previously, 542 (84.2%) had a history of
contraceptive use, 272 (42.6%) had a history of STIs, 116
(18.0%) had STIs that had been treated in the past
12 months, 345 (53.6%) were married or cohabiting, 227
(35.3%) had not completed secondary/high school
education, 340 (53.0%) were unemployed and 513
(79.7%) reported one lifetime sexual partner.
Prevalence of STIs
Table 3 shows the weighted prevalence of selected STIs
in the samples of women aged 15–49 years. The overall
STIs’ weighted prevalence (excluding HIV and HPV)
was 19.4%, (95% CI: 14.9–24.8) and individual preva-
lence for Trichomonas vaginalis (TV), Neisseria gonor-
rhoeae (NG), Chlamydia trachomatis (CT), Treponema
pallidum (syphilis) and genital warts (GW) was 8.46.0,
7.0, 1.4 and 2.0%, respectively. The overall weighted hr-
HPV prevalence and HIV prevalence was 46.2% (95% CI:
42.8–49.5), and 42.7% (95% CI: 35.7–46.2) respectively,
(Table 3) (detailed data shown in a previously published
article [38]). About 4.0% (95% CI: 2.3–6.0) had two or
more STIs (multiple infections) and 6.0% (95% CI: 4.3–
8.5) had triple infection (at least one STI, HIV and hr-
HPV infection) (Table 3). Among women with hr-HPV,
18.9% (95% CI: 13.1–26.3) had a single STI and 6.3%
(95% CI: 3.3–11.7) had multiple STIs. Among HIV posi-
tive women, 17.7% (95% CI: 11.5–26.9) had one STI,
while 4.2% (95% CI: 1.5–11.3) had multiple STIs
(Table 4). About 6.3% (95% CI: 4.4–8.9) women had
STIs, HPV and HIV combined coinfections.
Population burden estimates
Tables 3 and 4 show the population burden estimates.
Population burden estimates to extrapolate absolute
burden counts of the different STIs were made based on
the 2007–2030 population projections aligned to the
2014 population estimates of women aged 15–49 years.
The overall population burden was estimated at 72 990
(95% CI: 51 111–94 871) as depicted on Table 3. When
stratified by each STI, 30 132 (95% CI: 16 633–43 631)
were estimated to have TV, 22 055 (95% CI: 11 986–32
124) have NG, 25 024 (95% CI: 11 251–38 797) have CT,
5 072 (95% CI: 1 822–8 322) have Treponema pallidum
(syphilis), and 6111 (95% CI: 470–12692) have GW.
Multiple STIs estimates were 13995 (95% CI: 7 092–20
898) and triple STIs were 23 310 (95% CI: 14 193–32
427). Among HIV positive women, the population bur-
den counts for single STIs were 32 158 (95% CI: 20
200–44 115) and for multiple infection 10 798 (95% CI:
4 032–17 564). Among hr-HPV positive women the
population burden counts for single and multiple infec-
tion were 27 163 (95% CI: 14 941–39 386) and 6 367
(95% CI: 159–12 893), respectively) (Table 4).
Prevalence of STIs by selected socio-demographic
characteristics of the women
Table 5 shows the prevalence of STIs by selected socio-
demographic characteristics of the women, and the risk
factors associated with STIs (univariable and multivari-
able logistic regressions). The prevalence of STIs de-
creased with increasing age, with the highest burden
among the 15–19 and 24–29 age groups (29.2 and 27.0%
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respectively) (Table 5). There was no statistically significant
difference between age-group observed for all or individual
STIs, although the prevalence of CT was slightly higher
among women aged 15–19 years (12.1%, 95% CI: 3.4–35.5,
p = 0.32), NG was higher among 20–24 years old (12.1%,
95% CI: 5.4–25.1, p = 0.41) while TV was higher among
25–29 years old (13.9%, 95% CI: 10.6–18.1, p = 0.15) as
compared to all ages (data not shown).
The prevalence of STIs was significantly higher among
single women (26.4%) as compared to married women
(11.2%) (p = 0.001). Women with secondary/high school
education had a prevalence of 22.2% as compared to
women who had never been to school (9.1%). Un-
employed and self-employed women had a prevalence of
21.6, and 21.8% respectively as compared to employed
women (14.7%). There was no statistically significant dif-
ference between women who reported being pregnant
before as compared to women who had never been
pregnant (25.2% vs 18.3%, p = 0.323).
Based on the univariate analysis: the mean age, being
married, increasing number of pregnancies and not
using condoms with ones’ regular partner were inversely
associated with STIs’ risk. Significant differences in pro-
portions regarding those married (p < 0.001), the number
of sexual partners (p < 0.001) and contraceptive use by
age group (p < 0.001) was observed. Having two and
three sexual life-time partners was associated with an in-
creased risk OR = 5.1 (95% CI: 1.2–21.5) and OR = 8.4,
(95% CI: 1.3–54.2) respectively for STIs. Being hr-HPV
positive was significantly associated with increased risk
of STIs (OR = 2.1, 95% CI: 1.3–3.6). In the final logistic
regression model (multivariate analysis), factors inde-
pendently associated with increased risk of STIs were:
being employed (OR = 2.2, 95% CI: 1.0–4.7), self-
employed (OR = 2.8, 95% CI: 1.5–5.5) and hr-HPV posi-
tive status (OR = 2.0, 95% CI: 1.3–3.1). Being married,
mean age and not using a condom one’s with regular
partner were found to be inversely associated in the final
model (OR = 0.4, 95% CI: 0.3–0.7, OR = 0.92, 95% CI:
Table 2 Socio-demographic characteristics of the study
population (N = 655)
Demographics n (%)
Age: n (%)
Mean ± SD (range) 32 .2 ± 8.7
15–19 39 (6.1)
20–24 111 (17.2)
25–29 131 (20.3)
30–34 116 (18.0)
35–39 103 (16.0)
40–44 80 (12.4)
45–49 75 (11.6)
Marital status: n (%)
Single 266 (41.3)
Cohabiting 38 (5.9)
Married 307 (47.7)
Divorced/separated 22 (3.4)
Widow 11 (1.7)
Education: n (%)
Never been to school 24 (3.7)
Primary 130 (20.2)
Secondary/High 373 (57.9)
Tertiary 117 (18.2)
Occupation: n (%)
Unemployed 340 (53.0)
Employed 255 (39.8)
Self-employed 46(7.2)
Ever pregnant : n (%)
Yes 571 (88.7)
No 64 (9.9)
Missing 9 (1.4)
Age at first pregnancy: Mean age (SD) 19.4 (3.9)
No. pregnancies: n (%)
0 6 (1.0)
1 139 (24.3)
2 127 (22.2)
3+ 297(46.1)
Age Menarche: Mean (SD) 14.39 (1.7)
Age at first intercourse: Mean age (SD) 17.90 (2.9)
Number of Sexual life partner: n (%)
0 33 (5.1)
1 513 (79.7)
2 61 (9.5)
3+ 43 (6.7)
Currently using contraceptives: n (%)
Yes 542 (84.2)
Table 2 Socio-demographic characteristics of the study
population (N = 655) (Continued)
No 95 (14.8)
Missing 7 (1.1)
Ever had STI: n (%)
Yes 272 (42.6)
No 337 (52.7)
Don’t remember 30 (4.7)
STIs treated in the past 12 months: n (%)
Yes 116 (18.0)
No 520 (80.9)
Don’t know 7 (1.1)
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0.89–0.95, and OR = 0.5, 95% CI: 0.3–0.9) respectively,
as compared to not having a sexual life partner.
Individual STI association with HIV and hr-HPV was
assessed. There was a significant inverse association be-
tween HIV and CT (p = 0.001) but there was a significant
positive association between HIV and syphilis (p = 0.001).
There was a significant positive association between hr-
HPV and NG and CT (p = 0.020 and p = 0.001). A signifi-
cant association with TV and hr-HPV (p = 0.058) was
observed (results not shown).
Discussion
The current study in Swaziland shows a high prevalence
of STIs (19.4%), corresponding to 72 990 women of re-
productive age with STIs. Our data suggests that TV
was the most prevalent curable STI (8.4%) among those
examined in this study. Furthermore, the prevalence of
HIV remains significantly high (42.7%) in this popula-
tion. The prevalence of the STIs decreased with increas-
ing age however, differences by age groups were not
statistically significant. A high percentage of women in-
fected with hr-HPV had one STI (18.8%), while 6.3% had
multiple STIs. Single women were at higher risk of being
infected with STIs compared to married women (26.4%
vs 11.2%, p = 0.001). A proportion of the women had
triple co-infection (6.3%), interact either directly with
one another or indirectly via the host’s resources or
immune system. Studies have demonstrated that, as
compared to infections of single pathogen species, these
interactions within coinfected hosts can alter the trans-
mission, clinical progression and control of multiple in-
fectious diseases [39, 40]. In the final logistic regression
model, being employed, self-employed and hr-HPV
infection status were risk factors positively associated
with STIs.
In this study, we collected primary data and biological
specimens using a standardized methodology. This is the
first study evaluating the prevalence of STIs among
women of reproductive age not attending antenatal care
in Swaziland. We were able to extrapolate our results on
the prevalence of STIs as well as genital warts to the
female population in the same age groups of 15–
49 years-old using the 2007–2030 population projections
aligned to the 2014 population estimates [37]. Another
strength of our study is that STIs such as NG, TV and
CT were detected using the Gene Xpert PCR (Xpert
CT/NG and Xpert TV) which, is a highly sensitive
laboratory method for detecting genital infection. An
important limitation of the study is the lack of
generalizability of the results to the general Swazi female
population beyond the age groups studied (15–49 years).
In addition, since the study subjects were recruited from
heath care facilities, it is arguable that they may not be
truly representative of the general population. This could
have introduced a selection bias. However, weighting
was applied when reporting the summary results for the
whole study sample. Lastly, the study participants were
required to recall past events, which could result in
compromising the accuracy of information provided,
due to recall bias. Finally, due to limited resources for
our study we did not genotype or test for LR-HPVs.
The high prevalence of STIs (19.4%) in this population
indicates that STIs are a serious public health problem
in Swaziland. Our findings were consistent with previous
studies from similar populations across the Southern
African Development Community region (SADC) and
other sub-Saharan regions [13, 15, 41–43]. The preva-
lence of each of the STIs detected among the study
population was less than 10% (7.0% for CT, 6.0% for NG,
8.4% for TV and 1.4% for syphilis), but this is still high,
which compared to global estimates, where the
Table 3 The prevalence of sexually transmitted infections (STIs) among women aged 15–49 in Swaziland (n = 655)
STIs Positive (n) Crude Prevalence (%) Survey weighted prevalence % (95% CI) Population burdena 95% CI
Overall 114 17.4 19.4 (14.9–24.8) 72990 51111–94871
TV 51 4.7 8.4 (5.4–12.8) 30132 16633–43631
NG 35 5.2 6.0 (3.8–9.4) 22055 11986–32124
CT 38 5.8 7.0 (4.1–11.2) 25024 11251–38797
Treponema pallidum (syphilis) 9 1.2 1.4 (1.1–10.2) 5072 1822–8322
Genital warts 6 1.0 2.0 (1.0–11.4) 6111 470–12692
HIV 276 42.1 42.7 (35.7–46.2) 153276 127336–179216
Hr-HPV (n = 644) 273 42.1 46.2 (42.8–49.5) 174046 153294–194797
Multiple STIsb 20 3.1 4.0 (2.3–6.0) 13995 7092–20898
cTriple STIs (n = 644)d 38 5.9 6.3 (4.4–8.9) 23310 14193–32427
aPopulation burden estimates extrapolated (using sample statistics) based on the 2007–2030 population projections aligned to the 2014 population estimates
bMultiple STIs – having two or more of the screened 5 STIs
cTriple infection: at least one other STI including HIV and hr-HPV infection
dA total of 11 women had insufficient specimen for hr-HPV testing therefore for the analysis for Triple STIs done on N = 644
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Table 5 Risk factors associated with STIs among women aged 15–49 years in Swaziland (N = 655)
Risk factors STIs (Weighted Prevalence) Unadjusted (Univariate) Adjusted (Multivariable)
Number + ve/Total (%, 95% CI) OR (95% CI) P-value ORa (95% CI) P-value
Overall 114/655 19.3 (14.9–24.8)
Age
Mean ± SD (range) 114/655 27 .1 (25.9–28.2) 0.9 (0.8–0.9) 0.001 0.9 (0.8–0.9) <0.001
15–19 13/45 29.2 (14.3–59.4) 1 (ref)
20–24 26/110 22.7 (13.1–37.4) 0.7 (0.2–2.1) 0.520 …. ….
24–29 34/127 27.0 (19.0–38.1) 0.9 (0.4–2.1) 0.797 ….. ….
30–34 20/143 13.0 (6.0–3161) 0.4 (0.1–1.1) 0.081 …. ….
35–39 14/94 14.5 (7.7–28.8) 0.4 (0.1–1.2) 0.110 .... ….
40–44 6/78 6.9 (1.5–29.9) 0.2 (0.03–1.1) 0.067 …. ….
45–49 1/58 1.0 (0.1–8.7) 0.03 (0–0.3) 0.004 …. ….
Marital status
Single 66/271 26.4 (18.5–37.4) 1 (ref)
Living with partner/Cohabiting 9/38 24.2 (9.8–62.3) 0.89 (0.3–2.5) 0.819
Married 36/313 11.2 (6.7–18.9) 0.35 (0.2–0.6) 0.001 0.4 (0.3–0.7) 0.001
Divorced/separated 3/22 15.1 (4.9–38.3) 0.5 (0.13–1.9) 0.289 …. ….
widow 0/11 0 — — …. ….
Education:
Never been to school 2/24 9.4 (19.0–36.0 1 (ref)
Primary 23/133 21.4 (10.5–47.8) 2.6 (0.4–16.9) 0.299 …. ....
Secondary/High 78/380 22.2 (15.4–31.3) 2.7 (0.5–15.4) 0.243 …. …
Tertiary 11/118 7.3 (3.5–16.9) 0.8 (0.1–5.4) 0.777 …. ….
Occupation:
Unemployed 67/346 21.6 (14.2–32.9) 1 (ref) 1 (ref)
Employed 39/258 14.7 (9.8–22.0) 0.63 (0.34–1.16) 0.129 2.2 (1.0–4.7) 0.045
Self-employed 8/48 21.8 (8.0–47.4) 1.01 (0.32–3.19) 0.982 2.8(1.5–5.5) 0.002
Pregnant before
Yes 99/582 18.3 (13.5–24.4) 1 (ref)
No 13/64 25.2 (12.6–48.9) 1.51 (0.65–3.46) 0.323 …. ….
No. of pregnancies (Mean) 114/655 2.2 (1.9–2.5) 0.8 (0.7–0.9) 0.008 …. …
Age Menarche (Mean age) 114/655 13.97 (13.5–14.4) 0.9 (0.7–1.1) 0.166 …. ..
Age at first sex (mean age) 114/655 17.2 (16.5–17.9) 0.96 (0.9–1.1) 0.370 ….. …..
Number of sexual partners 2.0 (0.6–3.4) 1.3 (1. 4–1.5) <0.001 1.2 (0.9–1.5) 0.197
0 3/33 6.2 (14.2–23.6) 1 (ref) …. …
1 84/522 18.4 (14.2–23.6) 3.4 (1.0–12.3) 0.056 …. ….
2 16/62 25.1 (11.3–46.8) 5.1 (1.1–21.5) 0.028 …. ….
3+ 11/37 35.6 (15.7–53.3) 8.4 (1.3–54.2) 0.027 …. ….
Condom use with regular partner
Yes 93/457 21.6 (14.8–31.2) 1 (ref) 1 (ref)
No 20/194 13.1 (5.7–29.1) 0.5 (0.28–0.9) 0.022 0.5 (0.3–0.9) 0.034
Ever had STI
Yes 41/278 16.2 (10.9–23.4) 1 (ref)
No 63/342 19.8 (15.2–25.3) 1.28 (0.8–2.0) 0.246 …. ….
Don’t remember 7/30 31.8 (12.0–61.3) 2.42 (0.7–7.8) 0.136 …. ….
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prevalence for CT among women range from 2.4 to
6.9%, NG from 0.3% to 1.2, TV from 1.9 to 7.8% and
syphilis from 0.2 to 1.3 [44]. Results from the firstand
second STI sentinel surveillance surveys conducted in
2003 and 2005 respectively in Swaziland, showed that
the prevalence of STIs, such as CT, NG, TV and syphilis,
and other reproductive tract infections, such as bac-
terial vaginosis and candidiasis, continue to be among
the highest in the country [45, 46]. However, a de-
cline in syphilis has been noted in recent years. Ac-
cording to the 11th Sentinel Surveillance report 2008,
recent syphilis infection was tested using Treponema
pallidum haemagglutination (TPHA), and the preva-
lence was 1.9% while 4.7% showed a history of syph-
ilis infection by RPR results [47]. A comparison
between the 2008 report and recent syphilis infection
shows a decreasing trend (1.9%) compared to current
study findings (1.4%). The high prevalence of the cur-
able STIs in this population might be linked to the
limitation of syndromic STI management, which does
not give specific aetiological diagnosis; therefore, most
infections are missed by this approach [48, 49]. Al-
though syndromic management has proven to be
cost-effective in resource limited settings, our findings
demonstrate the evidence for the need of a strong
national STIs’ surveillance system.
HIV remains one of the major public health challenges
in Swaziland, with the highest prevalence among women
of reproductive age [50, 51]. This high prevalence re-
ported in our study was consistent with other studies.
However, our results were slightly higher as compared
to Bicego et al’s study on recent patterns in population–
based HIV among women age 18–49 years (42.7% vs.
39%) [50]. In a country that has the highest HIV preva-
lence in the world, the challenge remains to assist unin-
fected individuals in gaining access to high quality
prevention services, including early detection and
treatment of curable STIs.
The observed high prevalence of STIs in the younger
age groups as compared to the older age groups in our
study is consistent with other studies [41, 52, 53]. The
decreasing STIs prevalence with increasing age observed
in our study, might be the results of the high susceptibil-
ity of younger women, lack of protective immune
response development, and more risky behavior, such as
an earlier age at first intercourse, a high number of
sexual partners, and unprotected sex [52].
In this current study, single women and women living
with partners (but not married) had the highest preva-
lence of STIs. Similar evidence has been found in other
studies [54, 55]. In our multivariate analysis, married
women were 60% less likely to be at risk of STIs as com-
pared to single women (OR = 0.4). A similar outcome
was found in others studies showing being married is a
protective factor [48, 56].
As far as education is concerned, our findings have
shown that women with a lower level of education are
most likely to have an STI. Studies have shown that
women with less education have an increased risk of
STIs [13, 57, 58]. Kakaire et al. highlighted that women
with lower education tend to lack formal employment
and may be completely dependent on the male sexual
partner and unable to negotiate safer sex. They are less
likely to access STI preventative information and health-
care services [13]. According to Muula, unemployment
may leave women with limited alternatives where they
may resort to engaging in high risk behavior such as be-
coming sex workers or to engaging in transactional sex
in which they provide sex in exchange for money and
material resources from a partner [59]. However, our
study found that employed and self-employed women
were at high risk of STIs (OR: 2.2 and OR: 2.8 respect-
ively) as compared to unemployed women. The types of
employment might explain the high risk of STIs among
employed and self-employed women in our study and
the in which businesses they are involved. There is
Table 5 Risk factors associated with STIs among women aged 15–49 years in Swaziland (N = 655) (Continued)
STIs treated in the past 12 months
Yes 24/118 22.6 (13.5–35.5) 1 (ref)
No 89/529 18.7 (14.7–23.6 0.8 (0.5–1.4) 0.376 …. …..
Don’t know 1/7 13.9 (12.6–67.3) 0.6 (0.4–8.1) 0.654 …. ….
HIV Status:
Negative 55/373 17.7 (13.4–23.0) 1 (ref)
Positive 59/281 21.9 (15.2–30.4) 1.3 (0.9–2.0) 0.204 ….. ….
hr-HPV status:
Negative 46/371 13.7 (8.9–20.6) 1 (ref) 1 (ref)
Positive 64/273 25.2 (19.0–32.7) 2.1 (1.3–3.6) 0.007 2.0 (1.3–3.1) 0.002
The Bolded data shows the signficant results
aAdj. OR: Adjusted Odds Ratio for age, marital status, level of education, occupation, history of pregnancy, age at first sex, history of STIs, STIs treated in the past
12 months, HIV status
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evidence suggesting that women working in high-risk
occupation such bars, food facilities, guesthouses and
similar facilities are at high risk of STI infection [48].
In this study, the risk associated with STIs among
women with two or more sexual life-time partners was
five to eight times higher as compared to women with
no sexual partners in the univariate analysis. Our find-
ings were consistent with other studies which reported
that sexual activity with many partners increases the
odds of STIs [53, 54]. However, the association was not
statistically significant in our study following adjustment
for all possible confounding factors (age, marital status,
level of education, occupation, history of pregnancy, age
at first sex, history of STIs, STIs treated in the past
12 months, and HIV status), which negatively con-
founded this relationship. There was a very high collin-
earity between the number of sexual partners and some
of the confounding factors, which may have further
affected the coefficients in the stepwise multivariable
regression. Though evidence from studies done in South
Africa [41, 42], Zambia [60], and Tanzania [48] has
demonstrated that having more than one or concurrent
lifetime sexual partners was among the risk factors
associated with STIs.
Inconsistent condom use as a risk factor for STIs in
women has been demonstrated in other studies [61, 62].
In contrast to our study, not using condoms with regular
partners was inversely associated with STIs. The possible
plausible explanation of our findings might be that,
women who reported not using condoms with regular
partners had one faithful partner or they had been
treated for STIs prior to data collection. However, this
will require further investigation. Moreover, condoms
remain a critical part in a comprehensive and practical
approach to the prevention of STIs [63].
HIV positive status was not associated with STIs in both
analyses but when assessed by individual STIs, a signifi-
cant inverse association between HIV and CT, and signifi-
cant positive association between HIV and syphilis were
observed. No statistically significant association between
HIV and NG or TV was observed in the current study.
However, studies have indicated that depending on the
STI involved and the population, NG, CT, TV, HPV and
syphilis increase the risk of HIV acquisition and transmis-
sion from two to eight times or more [4, 6, 7]. Further-
more, biological findings support the mechanisms for
STIs increasing HIV acquisition and transmission
through direct mucosal disruption, recruitment of
HIV target cells to the genital tract, and by increased
HIV load in plasma and genital secretions [10]. High
levels of untreated STIs in sub-Saharan countries are
linked to high HIV transmission rates and have been
postulated to have contributed to the high prevalence
of HIV in the region [16].
A vital clinical and public health consequence of our
findings is that hr-HPV was the most significant risk fac-
tor associated with STIs infection in both univariate and
multivariate analysis (unadj-OR = 2.1 and Adj-OR = 2.0).
When assessing the association between hr-HPV and indi-
vidual STIs, there was a significant positive association be-
tween hr-HPV and NG and CT. The strong association
between HPV infection and STIs has been demonstrated
in previous studies, where infection with hr-HPV types,
was a risk factor for CT and NG infection [64–66]. These
findings are significantly of high importance for policy
and prevention programmes to include HPV infection in
the existing STIs prevention programmes in the country.
The curable STIs (CT, NG, TV, and syphilis), and HIV
and HPV are sexually transmitted infections, which
share the same transmission route and behavioural risk
factors. If the curable STIs are not treated, they can lead
to a variety of different health risks and greatly increase
HIV/HPV transmission risk with further chronic health
implications. Collectively, our data have shown the sig-
nificantly high prevalence of and association between
STIs and HIV/HPV coinfection, which tends to sub-
scribe to the new concept in which HIV and HPV infec-
tions may be bi-directional, each increasing the risk of
the other [67–69] STIs increase the risk of HIV/HPV
co-infection. The high hr-HPV/HIV coinfection with the
curable STIs and resultant high population burden has
implications for both cervical cancer and also for the
United Nations (UN) sustainable development goal 3,
target 3.3 (SDG 3) [70] (goal 3 aims to reduce new HIV
infection through ensuring health and well-being for all,
at every stage of life). The STIs are positively increasing
the risk of HIV/HPV acquisition, which will make it im-
possible for countries like Swaziland to achieve SDG 3
target 3.3. Therefore, STIs’ control and HPV vaccination,
combined with periodic HIV screening and referral to
early treatment is needed to end the HIV epidemic in
Swaziland.
Conclusion
In conclusion, although STIs may be treated and are
curable, they remain a major public health challenge in
Swaziland where HIV infection is highly prevalent. Our
study indicates that there is a need for a comprehensive
STI screening, surveillance and treatment programme in
the country.
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